Verucerfont

DB12512InvestigationalSmall molecule

Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.

Mechanism: Pharmacologically active on Corticotropin-releasing hormone receptor 1
Curator reviewed
Formula / weight: C₂₂H₂₆N₆O₂ · 406.49 g/mol (avg)
Code names: GSK-561,679 · GSK-561679A · NBI-77860

Resolves to

Compound

Structure

InChIKeyVKHVAUKFLBBZFJ-SFHVURJKSA-NSMILESCC[C@H](NC1=CC(C)=NC2=C(C(C)=NN12)C1=CC=C(OC)C=C1C)C1=NC(C)=NO1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Verucerfont, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.